Sign In

Carlo Bertozzi

Carlo Bertozzi is a professional in the pharmaceutical and biotechnology sectors, currently serving as the CEO and Co-Founder of InCephalo, a company focused on drug development. Prior to this role, he was the CEO of G7 Therapeutics, a Swiss biotech firm specializing in the development of novel medicines targeting G protein-coupled receptors (GPCRs) until its rebranding to Heptares Zurich in late 2016.2

Bertozzi is also recognized for his involvement with Veranova, where he is a member of the advisory board alongside other industry leaders. Veranova specializes in the development and manufacturing of complex active pharmaceutical ingredients (APIs) for the biotech and pharmaceutical sectors.14 His expertise and leadership contribute significantly to advancing therapeutic innovations in these fields.

On LinkedIn, Bertozzi's profile indicates he has a strong professional network and background in business management, having studied at IMD Business School in Zürich.3

Highlights

Veranova expands advisory board with appointment of two industry ...
Find out about Innosuisse's partners and members
Find out about Innosuisse's partners and members
Pentameric Ligand-gated Ion Channels : Insights from Computation

Related Questions

What is Carlo Bertozzi's role at InCephalo?
How did Carlo Bertozzi transition from G7 Therapeutics to InCephalo?
What are Carlo Bertozzi's key achievements at G7 Therapeutics?
What is the CHESS and SaBRE platform developed by G7 Therapeutics?
How does Carlo Bertozzi's experience at G7 Therapeutics benefit InCephalo?
Carlo Bertozzi
Carlo Bertozzi, photo 1
Carlo Bertozzi, photo 2
Add to my network

Location

Zürich Area, Switzerland